E-Greetings from the Allergy Advocacy Association

July 2021 e-news issue

Greetings! Along with warm sunshine and blue skies good news has arrived from Albany. Governor Andrew Cuomo has signed a new law making it much easier for New York State Department of Environmental Conservation police, park police and forest rangers to carry life-saving epinephrine! Many thanks to all legislators who voted in favor of this important legislation! Also in this issue, we provide an update on summer camp selections, possible new methods of administering epinephrine and an update on Dillon's Law and its' introduction into the US Congress.

FREE is always the BEST price! You can have Anaphylaxis Emergency Training direct from the internet into your home or office at NO COST to you or your organization!

Our Epi Near You NY anaphylaxis emergency training program is now VIRTUAL!

Our association would help provide: 

  • Free state approved training presentation;
  • New York State recognized certification;
  • Assistance for public entities to obtain a non-patient specific prescription for emergency epinephrine.

For more information on our next scheduled ENYNY seminar, visit our EpiNearYourNewYork page.

Best wishes from everyone at the Allergy Advocacy Association!

Governor Cuomo Signs Legislation Allowing Park Rangers to Administer Epi-Pens to Treat Allergic Reactions

As a direct result of Food Allergy Awareness Day NY at the end of May, Governor Andrew Cuomo has enacted S.4375/A.4652. The law authorizes Forest Rangers, Park Rangers and Environmental Conservation Police Officers to Possess and Administer Epinephrine through an Auto-Injector Device in NYS parks. Senator James Tedisco and assembly member Angelo Santabarbara share why this law is so important in protecting individuals with life-threatening allergies at risk for anaphylaxis.

Governor Cuomo Signs Legislation Allowing Park Rangers to Administer Epi-Pens to Treat Allergic Reactions

Govenor Andrew Cuomo signing bill

Legislation (S.4375/A.4652) Authorizes Forest Rangers, Park Rangers and Environmental Conservation Police Officers to Possess and Administer Epinephrine through an Auto-Injector Device Legislation Signed as New York State Parks See Record Visitation in 2020

Continue Reading

Grothman Introduces Dillon’s Law In US Congress

After their son Dillon suffered a fatal attack of anaphylaxis after being stung by a bee, Angel and George Mueller became dedicated advocates for individuals and families with life-threatening allergies. Since being enacted in Wisconsin, Dillon's Law has saved several lives; Minnesota and Indiana promptly adopted the same legislation. Now Dillon's Law has gone to Washington DC; its' introduction in Congress provides hope to all allergy activist advocates across America.

Grothman Introduces Dillon’s Law In US Congress

Dillon Mueller with tractor
Dillon Mueller
June 22, 2021

By Timothy Svoboda
Washington, DC

Congressmen Glenn Grothman (WI-06) has introduced Dillon’s Law, a bill that will incentivize states to allow “good Samaritans” to save lives. This bill will allow states to use existing federal grant money for preventative health services to be used to train individuals to carry and administer epinephrine.

Continue Reading

Intranasal Delivery of Emergency Epinephrine Takes Another Step Toward Realization

Concerning anaphylaxis emergencies and epinephrine, imagine if an "Epi nasal spray" became a viable treatment option instead of an intermuscular EAI injection device. It might happen sooner that you might think; new devices are being developed that don't require using a needle. And some of them do look very promising.

Intranasal Delivery of Emergency Epinephrine Takes Another Step Toward Realization

Intranasal Epi device

Dave Bloom By Dave Bloom
2021/07/07

We’ve been following the progress of ARS Pharma’s and Bryn Pharma’s intranasal emergency epinephrine devices as they make their way through clinical trials. These devices are meant to provide a needle-free alternative to today’s auto-injectors for the treatment of anaphylaxis.

Now, yet another company is reporting promising results in the race to bring an intranasal device to market, although this one does so differently.

Nasus Pharma based in Tel Aviv is reporting positive results from a pilot study of their FMXIN002 candidate. Unlike the other devices, this device stores and delivers epinephrine in powder form.

Continue Reading